The report states Piramal Pharma's EBITDA grew 120% YoY ahead of estimates, with upgraded revenue growth guidance to 19-20% driven by CDMO and CHG momentum.
Read this note →Piramal Pharma Limited
NSE PPLPHARMA BSE 543635 INE0DK501011
0 filings · 0 analysed
246.37
+3.56%
over 5 days
Prices from Yahoo Finance, NSE close, delayed — indicative only, not for dealing.
Targets, and what happened next
What each house published, and where the price has gone since. Orivam issues no calls of its own and takes no view on these.
| House | Published | Call | Entry | Target | Now | Progress | Standing |
|---|---|---|---|---|---|---|---|
| HDFC Securities | 29 Oct 2026, 06:40 | long | 230.78 | 270.00 | 239.32 | 22% | open by 2027-10-29 |
| HDFC Securities | 07 Oct 2026, 15:25 | long | 203.01 | 240.00 | 238.91 | 97% | hit |
Deadlines: 0 stated by the house, the rest set by Orivam’s convention — ten trading days for a technical call, twelve months for a price target. A target with no date cannot be judged, so one has to be chosen.
What the desks said
The report expects 14% YoY revenue growth led by CDMO and CHG businesses, with EBITDA margin expansion though PAT remains negative.
Read this note →The report notes Piramal is expected to post a net loss in 2QFY27 despite 41.0% YoY EBITDA growth, and underwent a USFDA inspection at its Morpeth, UK facility with 7 observations.
Read this note →Announcement timeline
No filings stored for this company yet.
Never miss the next one.
Orivam emails what the research desks published each trading morning, attributed and linked to the original notes. Free.
Get the daily brief